In a further randomized, double-blind, placebo-controlled phase III study in mild-to-moderate AD, rosiglitazone monotherapy failed to show any benefit in cognition or in global function in ApoE ε4 negative subjects [67]. This evidence concerns the gene APOE and Alzheimer disease.